Remarkable Progress in Clinical Trials: CBT-009 and CBT-004

We are proud to announce that  CBT-009, our novel ophthalmic formulation of atropine indicated for the treatment of juvenile myopia, has reached agreement with FDA to enter into Phase III clinical trial in the USA. We have submitted our application to FDA for conducting a Phase II clinical trial in the United States to test a first-in-class drug […]

Seeing Life Better Through Medicine

Imagine a world where everyone can experience the joy and beauty of clear vision. At Cloudbreak, our mission is centered around the belief that vision is not just a sense but a gateway to a more fulfilling life. We strive to empower individuals by improving their vision and reducing the burden of eye disease. Through […]

Cloudbreak: A Clinical-Stage Company Dedicated to Improving Vision Health

Perhaps you are unfamiliar with us and unsure of what motivates us to become a mission-driven company. Today, we are excited to share our story with you. Cloudbreak is a clinical-stage biotechnology company on a mission to improve the vision quality of people worldwide. We aim to help them see life better through medicine by […]

Cloudbreak Pharma Named a Potential Unicorn for 2023

  On June 20th, 2023, Greatwall Strategy Consultants (GEI) released the “2023 China Potential Unicorns Research Report”. Cloudbreak Pharma is honoured to be named one of the potential unicorn companies in China. The report showed that Suzhou ranked third in the country and first in the province in terms of number of potential unicorns with […]

Cloudbreak Pharma Inc. and Centre for Eye and Vision Research Ltd. sign a memorandum of understanding for strategic cooperation in Hong Kong

On May 17th, Cloudbreak Pharma Inc. (Cloudbreak) and Centre for Eye and Vision Research Ltd. (CEVR) signed a memorandum of understanding for strategic cooperation at the Asia Summit on Global Health (ASGH) in Hong Kong. The parties intend to explore opportunities to collaborate on research in ocular science and have reached a preliminary understanding of […]